A Phase I Study of Entinostat in combination with Enzalutamide for treatment of patients with castration-resistant prostate cancer (CRPC)

Objectives:

  1. Determine the safe dose of Entinostad when given in combination with Enzalutamide in CRPC patients
  2. Determine the safety profiles of the combination of Entinostat and Enzalutamide

Candidates: Patients who have CRPC progressing on ADT and indicated for Enzalutamide as the next line of treatment

Clinical Program: Urological Oncology Program
Cancer Type & Condition: Prostate Cancer
Principal Investigator: Jianqing Lin
Contact Info: 2029940450